GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (NYSE:BLCO) » Definitions » EBITDA

Bausch & Lomb (Bausch & Lomb) EBITDA : $532 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb EBITDA?

Bausch & Lomb's EBITDA for the three months ended in Mar. 2024 was $119 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $532 Mil.

During the past 12 months, the average EBITDA Growth Rate of Bausch & Lomb was -0.40% per year. During the past 3 years, the average EBITDA Growth Rate was -10.60% per year. During the past 5 years, the average EBITDA Growth Rate was -11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 6 years, the highest 3-Year average EBITDA Growth Rate of Bausch & Lomb was -8.80% per year. The lowest was -12.90% per year. And the median was -10.60% per year.

Bausch & Lomb's EBITDA per Share for the three months ended in Mar. 2024 was $0.34. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.52.

During the past 12 months, the average EBITDA per Share Growth Rate of Bausch & Lomb was -0.50% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -10.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 6 years, the highest 3-Year average EBITDA per Share Growth Rate of Bausch & Lomb was -8.80% per year. The lowest was -12.90% per year. And the median was -10.70% per year.


Bausch & Lomb EBITDA Historical Data

The historical data trend for Bausch & Lomb's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb EBITDA Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Get a 7-Day Free Trial 932.00 732.00 733.00 598.00 499.00

Bausch & Lomb Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.00 132.00 123.00 158.00 119.00

Competitive Comparison of Bausch & Lomb's EBITDA

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch & Lomb's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Bausch & Lomb's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Bausch & Lomb's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, Bausch & Lomb's EBITDA was $499 Mil.

Bausch & Lomb's EBITDA for the quarter that ended in Mar. 2024 is calculated as

Bausch & Lomb's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2024, Bausch & Lomb's EBITDA was $119 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $532 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Bausch & Lomb  (NYSE:BLCO) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Bausch & Lomb EBITDA Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bausch & Lomb (Bausch & Lomb) Business Description

Traded in Other Exchanges
Address
520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Executives
Luc Bonnefoy officer: President,Surgical C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Andrew J. Stewart officer: See remarks C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Bailey A Robert D officer: EVP & Chief Legal Officer C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Brent L Saunders director, officer: CEO and Chair 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Brett Icahn director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Gaoxiang Hu director 16690 COLLINS AVE., SUITE PH-1, SUNNY ISLES BEACH FL 33160
Bausch Health Companies Inc. 10 percent owner 2150 ST. ELZEAR BLVD. WEST, LAVAL, QUEBEC A8 H7L 4A8
Sarah B Kavanagh director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Nathalie D. Bernier director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Yehia Hashad officer: EVP, R&D and CMO C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Frederick Munsch officer: SVP, Controller and CAO C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon officer: Please see remarks C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Ross Thomas W. Sr. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann officer: Please see remarks C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Russel C Robertson director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807